CN104432001A - Edible composition and use thereof - Google Patents
Edible composition and use thereof Download PDFInfo
- Publication number
- CN104432001A CN104432001A CN201310430441.0A CN201310430441A CN104432001A CN 104432001 A CN104432001 A CN 104432001A CN 201310430441 A CN201310430441 A CN 201310430441A CN 104432001 A CN104432001 A CN 104432001A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- edible composition
- group
- capsule
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 239000006041 probiotic Substances 0.000 claims abstract description 64
- 235000018291 probiotics Nutrition 0.000 claims abstract description 64
- 239000008280 blood Substances 0.000 claims abstract description 52
- 210000004369 blood Anatomy 0.000 claims abstract description 52
- 239000001963 growth medium Substances 0.000 claims abstract description 47
- 230000000529 probiotic effect Effects 0.000 claims abstract description 42
- 230000000968 intestinal effect Effects 0.000 claims abstract description 24
- 230000036039 immunity Effects 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims description 80
- 241000894006 Bacteria Species 0.000 claims description 70
- 239000007788 liquid Substances 0.000 claims description 55
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 36
- 241000193171 Clostridium butyricum Species 0.000 claims description 25
- 238000012258 culturing Methods 0.000 claims description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 17
- 241000186394 Eubacterium Species 0.000 claims description 15
- 241000605947 Roseburia Species 0.000 claims description 14
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 229910001868 water Inorganic materials 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 7
- 241000186000 Bifidobacterium Species 0.000 claims description 5
- 241001464948 Coprococcus Species 0.000 claims description 5
- 244000199866 Lactobacillus casei Species 0.000 claims description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 5
- 244000057717 Streptococcus lactis Species 0.000 claims description 5
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 241000588914 Enterobacter Species 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 4
- 241000194036 Lactococcus Species 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 241001608234 Faecalibacterium Species 0.000 claims description 3
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 241000193749 Bacillus coagulans Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- 241000222511 Coprinus Species 0.000 claims description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 2
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 241000398180 Roseburia intestinalis Species 0.000 claims description 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 229940054340 bacillus coagulans Drugs 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000007857 degradation product Substances 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims 1
- 241000605902 Butyrivibrio Species 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 241000589236 Gluconobacter Species 0.000 claims 1
- 240000002605 Lactobacillus helveticus Species 0.000 claims 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims 1
- 241001468157 Lactobacillus johnsonii Species 0.000 claims 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 229940068140 lactobacillus bifidus Drugs 0.000 claims 1
- 229940054346 lactobacillus helveticus Drugs 0.000 claims 1
- 230000001603 reducing effect Effects 0.000 abstract description 22
- 230000001105 regulatory effect Effects 0.000 abstract description 16
- 229920000157 polyfructose Polymers 0.000 description 29
- 238000004806 packaging method and process Methods 0.000 description 23
- 239000000843 powder Substances 0.000 description 22
- 239000000463 material Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- 108010010803 Gelatin Proteins 0.000 description 18
- 229920000159 gelatin Polymers 0.000 description 18
- 239000008273 gelatin Substances 0.000 description 18
- 235000019322 gelatine Nutrition 0.000 description 18
- 235000011852 gelatine desserts Nutrition 0.000 description 18
- 238000005406 washing Methods 0.000 description 18
- 239000011248 coating agent Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 17
- 238000001035 drying Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 241000193830 Bacillus <bacterium> Species 0.000 description 11
- 235000013871 bee wax Nutrition 0.000 description 11
- 239000012166 beeswax Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 239000002985 plastic film Substances 0.000 description 9
- 229920006255 plastic film Polymers 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 238000011218 seed culture Methods 0.000 description 9
- 241000193403 Clostridium Species 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000007766 cera flava Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 6
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 229960002433 cysteine Drugs 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007836 KH2PO4 Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000193163 Clostridioides difficile Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000589232 Gluconobacter oxydans Species 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000186428 Propionibacterium freudenreichii Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/137—Delbrueckii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/157—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/161—Mesenteroides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an edible composition, comprising a probiotic culture. The probiotic culture is obtained by cultivating probiotics by using a culture medium. The edible composition disclosed by the invention has the functions of adjusting intestinal flora, regulating blood sugar level, reducing blood fat and improving the immunity.
Description
Technical Field
The present invention relates to the field of food products, in particular to edible compositions and uses thereof.
Background
The probiotics is a kind of active microorganism beneficial to a host, and is planted in the intestinal tract and the reproductive system of a human body, and common beneficial bacteria in the human body mainly comprise clostridium butyricum, lactic acid bacteria, bifidobacteria and the like. The probiotics can produce beneficial physiological effects on the host by regulating the host mucous membrane and system immunity and improving the balance of the intestinal tract nutrition and flora, thereby playing the roles of improving the composition of the host intestinal flora, promoting the digestion and absorption of nutrient substances, inhibiting harmful bacteria and harmful substances and the like.
At present, hundreds of probiotic products are developed abroad, and there are various product types of common food, health care products and medicines, including yoghurt, yoghurt and sour soybean milk containing probiotics, and oral liquid, tablets, capsules, powder, bacteriostatic spray and the like containing various probiotics. However, the mode of combined administration by taking the probiotic culture as an adjuvant has not been developed yet.
Disclosure of Invention
The present invention aims to solve at least one of the above technical problems to a certain extent. To this end, it is an object of the present invention to propose an edible composition comprising a culture of probiotic bacteria, which has the efficacy of modulating the intestinal flora, lowering blood sugar, lowering blood lipids and enhancing immunity.
The existing health care products or medicines of probiotics take simple thalli as raw materials, or are added with prebiotics such as polyfructose, cottonseed galactooligosaccharide, xylooligosaccharide and the like for combined administration. However, the mode of combined administration by taking the probiotic culture as an adjuvant has not been developed yet. The inventor of the invention finds that the culture in the probiotic culture solution is rich in nutrition, and metabolites, vitamins, amino acids, digestive enzymes, organic acids, polysaccharides, unknown growth factors and the like of the probiotics can effectively promote the reproduction of beneficial bacteria in intestinal tracts and improve the gastrointestinal flora of animals.
To this end, in one aspect of the invention, an edible composition is provided. According to a particular embodiment of the invention, the composition comprises a culture of probiotics, wherein the culture of probiotics is obtained by culturing the probiotics with a culture medium. The edible composition is remarkably superior to single probiotics or the combination of the probiotics and prebiotics in the aspects of regulating the proliferation of beneficial flora in human intestinal tracts, reducing blood sugar, reducing blood fat and the like in a combined mode of the probiotics and the culture solution thereof.
The edible composition disclosed by the invention is prepared by combining probiotics and culture solution thereof, all raw materials are taken from nature, no chemical preparation is contained, and the edible composition is free from toxic and side effects, safe and reliable; the raw materials are wide in source and easy to obtain, the formula compatibility is scientific and reasonable, the curative effect is exact, the synergistic effect is achieved, and the traditional Chinese medicine composition can be effectively used for regulating intestinal flora, reducing blood sugar, reducing blood fat and the like.
According to the specific embodiment of the invention, the edible composition of the invention is proved by the eating tests of people to have no toxic or side effect, has the obvious functions of reducing blood sugar and blood fat, regulating intestinal flora, improving immunity and the like, and meets the requirements and development trends of health care products. The edible composition can remarkably reduce the content of serum total cholesterol and triglyceride in blood, increase the level of high-density lipoprotein and regulate intestinal flora; in the aspect of regulating blood sugar, the fasting blood sugar of the patient can be obviously reduced. The composition is suitable for hyperglycemia, hyperlipidemia, obesity, and the elderly, and can be taken daily to achieve the purpose of protecting health by improving lipid metabolism, improving blood flow, enhancing immunity, etc., from the viewpoint of permanent cure.
In addition, the edible composition realizes convenient and obvious health care effects of reducing blood sugar, reducing blood fat, improving immunity of organisms and the like by reasonably matching pure natural raw materials, has obvious drug effect, good safety and stable quality, and can be stored for a long time, so the edible composition can provide a new choice for daily health care of people.
According to an embodiment of the present invention, the probiotic included in the composition may be any genus of probiotic, and according to a specific embodiment of the present invention, the probiotic may be at least one selected from the group consisting of Coprococcus (Faecalibacterium), Eubacterium (Eubacterium), rosenbergia (Roseburia), Coprococcus (Coprococcus), Bifidobacterium (Bifidobacterium), vibrio butyrate (butyivibrio), lactobacillus (bactobacterium), and Lactococcus (Lactococcus). Therefore, the effects of the edible composition on regulating the proliferation of beneficial flora in the intestinal tract of a human body, reducing blood sugar, reducing blood fat and the like can be further improved.
According to an embodiment of the present invention, the specific probiotic bacteria contained in the composition are not particularly limited, and according to an embodiment of the present invention, the probiotic bacteria may be selected from Eubacterium rectus (Eubacterium recetal), gluconobacter gluconicum (Roseburia inuivorans), rosenbergia enterocolitica (Roseburia intestinalis), coprobacterium pratense (Faecalibacterium prausnitzii), clostridium butyricum, bacillus coagulans, bifidobacterium bifidum, bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, lactobacillus adolescentis, lactobacillus delbrueckii subspecies bulgaricus, lactobacillus acidophilus, streptococcus thermophilus, lactobacillus casei, lactobacillus reuteri, bifidobacterium lactis, lactobacillus casei, lactobacillus crispatus, lactobacillus bulgaricus, lactobacillus gasseri, lactobacillus fermentum, lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus casei, lactobacillus paracasei, lactobacillus plantarum, lactobacillus paracasei, lactobacillus plantarum, lactobacillus paracasei, At least one of Lactobacillus salivarius, Propionibacterium freudenreichii subspecies, lactococcus lactis subspecies lactis, lactococcus lactis subspecies cremoris, lactococcus lactis (diacetyl subspecies) and Leuconostoc mesenteroides. Therefore, the effects of the edible composition on regulating the proliferation of beneficial flora in the intestinal tract of a human body, reducing blood sugar, reducing blood fat and the like can be further improved.
According to an embodiment of the present invention, the type of the above-mentioned medium is not particularly limited, and according to an embodiment of the present invention, the medium may be a solid medium or a liquid medium, and the components contained in the medium are not particularly limited, and according to an embodiment of the present invention, the medium may include a carbon source, a nitrogen source, a growth factor, inorganic salts, and water. According to embodiments of the present invention, the carbon source may be at least one selected from the group consisting of saccharides, organic acids, alcohols, and lipids, the nitrogen source may be at least one selected from the group consisting of proteins and their degradation products of varying degrees, ammonium salts, and nitrates, and the growth factor may be at least one selected from the group consisting of vitamins, amino acids, purines, and pyrimidine bases. Therefore, the living quality of the probiotics can be further improved, so that the edible composition contains more live probiotics as much as possible, and the effects of the edible composition on the aspects of regulating the proliferation of beneficial flora in the intestinal tract of a human body, reducing blood sugar, reducing blood fat and the like are further improved.
According to an embodiment of the present invention, the edible composition may be prepared into any dosage form, and according to an embodiment of the present invention, the edible composition may be in the form of a capsule or an oral liquid, so that it is more convenient to eat, so as to exert its effects of regulating the proliferation of beneficial bacteria in the intestinal tract of a human body, reducing blood sugar, reducing blood fat, and the like.
In another aspect of the invention, the invention provides a food product. According to a particular embodiment of the invention, the food product comprises an edible composition as described above. According to the specific embodiment of the invention, the food can be eaten in daily life to achieve the effects of regulating the proliferation of beneficial flora in the intestinal tract of a human body, reducing blood sugar, reducing blood fat and the like. Thus, the food may be a functional food or a health food.
In a further aspect of the invention, the invention provides the use of an edible composition as hereinbefore described in the manufacture of a preparation for use in at least one of modulating the intestinal flora, lowering blood glucose, lowering blood lipid and enhancing immunity according to a specific embodiment of the invention. The preparation contains the edible composition, so that the composition has the effect of increasing the number of probiotics in intestinal tracts and further has the effect of regulating the intestinal flora. Therefore, the preparation prepared from the edible composition can effectively improve the effects of the preparation in regulating intestinal flora, reducing blood sugar and blood fat, improving immunity and the like.
In a further aspect of the invention, the present invention proposes the use of an edible composition or food product as hereinbefore described for modulating the intestinal flora of an animal. The inventor finds that the quantity of probiotics in the intestinal tract of animals can be obviously increased by eating the edible composition or the food, and the aim of effectively regulating the balance of the intestinal flora is fulfilled. Therefore, the edible composition or food can be effectively used for treating and preventing enteritis, diarrhea and other diseases caused by intestinal flora imbalance by eating.
In a further aspect of the invention, a method of modulating the intestinal flora is provided, according to a particular embodiment of the invention, by administering to an animal an edible composition or food product as described above. According to the embodiment of the invention, the method can improve the quantity of probiotics supplied to the intestinal tract of the animal, effectively regulate the balance of intestinal flora of the animal, and further achieve the aims of effectively regulating the blood sugar and the blood pressure of the animal and improving the immunity through the action of healthy intestinal flora.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Detailed Description
The invention will now be described with reference to specific examples, which are intended to be illustrative only and not to be limiting in any way.
EXAMPLE 1 preparation of probiotic culture Medium
1. Clostridium butyricum and clostridium butyricum culture media:
tryptic casein: 5.0g
Peptone (pepsin digestion): 5.0g
Yeast cream: 10.0g
Resazurin: 1.0mg
CaCl2x2H2O：0.25g
MgSO4x7H2O：0.5g
K2HPO4：1.0g
KH2PO4：1.0g
NaHCO3：10.0g
NaCl：2.0g
Cysteine-HCl x H2O：0.5g
Add ddH20 volume is added to 1L, and the pH value is adjusted to 7.0.
2. A third clostridia culture medium:
beef extract: 20.0g
Peptone: 30.0g
Yeast cream: 5.0g
K2HPO4：5.0g
Resazurin: 1.0mg
Glucose: 4.0g
Cellobiose: 1.0g
Maltose: 1.0g
Soluble starch: 1.0g
Add ddH2The volume of O is adjusted to 1L, and the pH value is adjusted to 7.0.
3. Roseburia culture medium
Tryptic casein: 10.0g
Yeast cream: 5.0g
Meat juice: 5.0g
Soybean flour peptone: 5.0g
Glucose: 5.0g
K2HPO4：3.0g
MgSO4x7H2O：0.7g
MnSO4x H20：0.05g
Tween80：1.0ml
NaCl：7.00g
CaCl2x2H2O：0.25g
KH2PO4：1.0g
NaHCO3：10.0g
Cysteine-HCl x H2O：0.5g
Resazurin (25 mg/100 ml): 4.0ml
Add ddH2The volume of O is adjusted to 1L, and the pH value is adjusted to 6.8.
4. Lactobacillus reuteri culture medium:
tryptic casein: 10.0g
Meat juice: 10.0g
Yeast cream: 5.0g
Glucose: 20.0g
Tween80：1.0g
K2HPO4：2.0g
Na-acetate：5.0g
（NH4）2citrate：2.0g
Add ddH2The volume of O is adjusted to 1L, and the pH value is adjusted to 6.2-6.5.
5. Butyric acid bacteria and butyric acid bacteria culture medium
Corn starch: 10.0g
Beef peptone: 10.0g
Yeast cream: 5.0g
Sodium acetate: 3.0g
NaCl：5.0g
CaCO3：3.0g
MgSO4x7H2：0.5g
Cysteine-HCl x H2O：0.5g
Resazurin (25 mg/100 ml): 4.0ml
Add ddH2The volume of O is adjusted to 1L, and the pH value is adjusted to 7.0.
6. Culture medium for rectal fungi
Tryptic casein: 5.0g
Peptone: 5.0g
Yeast cream: 10.0g
Beef extract: 5.0g
Glucose: 5.0g
K2HPO4：3.0g
Tween80：1.0ml
Cysteine-HCl x H2O：0.5g
Resazurin: 1.00mg
CaCl2x2H2O：0.25g
MgSO4x7H2O：0.50g
KH2PO4：1.0g
NaHCO3：10.0g
NaCl：2.00g
Haemin solution：10.0ml
Vitamin K1solution：0.2ml
Add ddH2The volume of O is adjusted to 1L, and the pH value is adjusted to 7.0.
7. Culture medium for coprinus pusillus
KH2PO4：6.0g
NaCl：12.0g
(NH4)2SO4：6.0g
CaCl2x2H2O：1.6g
MgSO4x7H2O：2.5g
K2HPO4：0.3g
Tryptic casein: 2.0g
Yeast cream: 0.5g
Volatile fatty acid mixture: 3.1ml
Hemin: 1.0mg
Glucose: 0.5g
Maltose: 0.5g
Cellobiose: 0.5g
Soluble starch: 0.5g
Glycerol: 0.5g
Na2CO3：4.0g
Resazurin: 1.0mg
Cysteine-HCl x H2O：0.25g
Na2S x9H2O：0.25g
Add ddH2O constant volume is 1L, and the pH is adjusted to 6.7-6.8
Volatile fatty acid mixture:
acetic acid: 4.25ml
Propionic acid: 1.50ml
Butyric acid: 1.00ml
n-pentanoic acid: 0.25ml
Isobutyric acid: 0.25ml
DL-2-methylbutyric acid: 0.25ml
Isovaleric acid: 0.25ml
Example 2 preparation of probiotics and compositions thereof
1. Preparation of clostridium butyricum viable bacteria capsule
Culturing Clostridium butyricum strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active powder, making into capsule wall material with gelatin, using PVP as bottom coat, coating with beeswax, and packaging with No. 0 capsule to obtain Clostridium butyricum capsule with viable count not less than 1.0 x 108CFU/g。
2. Preparation of clostridium butyricum viable bacteria capsule containing polyfructose
Culturing Clostridium butyricum strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active powder, adding polyfructose according to the number of viable bacteria of Clostridium butyricum, and making the number of viable bacteria not less than 1.0 x 108CFU/g, the addition of polyfructose is not less than 4g, gelatin is used for preparing a capsule wall material, PVP is used for making a bottom coat, beeswax is used for carrying out outer-layer coating, and the capsule is packaged by a No. 0 capsule, so that the clostridium butyricum capsule is obtained.
3. Preparation of clostridium butyricum viable bacteria oral liquid
Inoculating clostridium butyricum into a liquid seed culture medium, and performing anaerobic culture at a proper temperature to obtain probiotic seed liquid. Inoculating probiotic seed solution into sterilized fermentation culture medium of Clostridium butyricum with total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 x 108CFU/ml。
4. Preparation of live butyric acid bacteria capsule
Culturing butyric acid bacteria strain with liquid or solid culture medium, collecting and washing bacteria, and drying to obtainActive bacteria powder; making capsule wall material with gelatin, using PVP as bottom coat, coating with Cera flava, and packaging with No. 0 capsule to obtain butyric acid bacteria capsule with bacteria number not less than 1.0 x 108CFU/g。
5. Preparation of viable bacteria capsules of butyric acid bacteria containing polyfructose
Culturing butyric acid bacteria strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active bacteria powder, and adding polyfructose according to viable count of butyric acid bacteria to make viable count not less than 1.0 × 108CFU/g, polyfructose additive amount not less than 4g, making into capsule wall material with gelatin, using PVP as bottom coat, coating with Cera flava, and packaging with No. 0 capsule to obtain butyric acid bacteria capsule.
6. Preparation of live butyric acid bacteria oral liquid
Inoculating butyric acid bacteria into liquid seed culture medium, and performing anaerobic culture at proper temperature to obtain probiotic seed liquid. Inoculating probiotic seed liquid into sterilized butyric acid bacteria fermentation culture medium according to total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 x 108CFU/ml。
7. Preparation of live butyric acid bacteria capsule
Culturing butyric acid bacteria strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active bacteria powder, making into capsule wall material with gelatin, using PVP as bottom coat, coating with beeswax, and packaging with No. 0 capsule to obtain butyric acid bacteria capsule with viable count not less than 1.0 x 108CFU/g。
8. Preparation of viable bacteria capsules of butyric acid bacteria containing polyfructose
Culturing butyric acid bacteria strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active bacteria powder, and adding polyfructose according to viable count of butyric acid bacteria to make viable count not less than 1.0 × 108CFU/g, polyfructose additive amount not less than 4g, making capsule wall material with gelatin, making bottom coat with PVP, and using beeCoating wax, and packaging with No. 0 capsule to obtain butyric acid bacteria capsule.
9. Preparation of live butyric acid bacteria oral liquid
Inoculating butyric acid bacteria into liquid seed culture medium, and performing anaerobic culture at proper temperature to obtain probiotic seed liquid. Inoculating probiotic seed liquid into sterilized butyric acid bacteria fermentation culture medium according to total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 x 108CFU/ml。
10. Preparation of viable bacteria capsule of clostridium third
Culturing third clostridium strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active powder, making into capsule wall material with gelatin, using PVP as bottom coat, coating with beeswax, and packaging with No. 0 capsule to obtain third clostridium capsule with viable count not less than 1.0 x 108CFU/g。
11. Preparation of third clostridium viable bacteria capsule containing polyfructose
Culturing Clostridium difficile strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active bacteria powder, adding polyfructose according to viable count of Clostridium difficile to make viable count not less than 1.0 x 108CFU/g, polyfructose additive amount not less than 4g, making into capsule wall material with gelatin, using PVP as bottom coat, coating with Cera flava, and packaging with No. 0 capsule to obtain Clostridium third capsule.
12. Preparation of third clostridium viable bacteria oral liquid
Inoculating Clostridium difficile into the liquid seed culture medium, and performing anaerobic culture at a proper temperature to obtain probiotic seed liquid. Inoculating probiotic seed liquid into sterilized fermentation culture medium of Clostridium third bacteria in a total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 × 108CFU/ml。
13. Preparation of clostridium butyricum viable bacteria capsule
Culturing Clostridium butyricum strain with liquid or solid culture medium, collecting and washing thallus, drying to obtain active powder, making capsule wall material with gelatin, using PVP as bottom coat, coating with beeswax, and packaging with No. 0 capsule to obtain Clostridium butyricum capsule with viable count not less than 1.0 x 108CFU/g。
14. Preparation of clostridium butyricum viable bacteria capsule containing polyfructose
Culturing Clostridium butyricum strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active powder, adding polyfructose according to the viable count of Clostridium butyricum, and making the viable count not less than 1.0 x 108CFU/g, the addition of polyfructose is not less than 4g, gelatin is used for preparing a capsule wall material, PVP is used for making a bottom coat, beeswax is used for carrying out outer-layer coating, and the capsule is packaged by a No. 0 capsule, so that the clostridium butyricum capsule is obtained.
15. Preparation of clostridium butyricum viable bacteria oral liquid
Inoculating clostridium butyricum into a liquid seed culture medium, and performing anaerobic culture at a proper temperature to obtain probiotic seed liquid. Inoculating probiotic seed solution into sterilized Clostridium butyricum fermentation culture medium according to total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 x 108CFU/ml。
16. Preparation of viable lactobacillus reuteri capsule
Culturing Lactobacillus reuteri strain with liquid or solid culture medium, collecting and washing thallus, drying to obtain active powder, making capsule wall material with gelatin, using PVP as bottom coat, coating with beeswax, and packaging with No. 0 capsule to obtain Lactobacillus reuteri capsule with viable count not less than 1.0 x 108CFU/g。
17. Preparation of viable lactobacillus reuteri capsule containing polyfructose
Liquid for lactobacillus reuteri strainOr culturing in solid culture medium, collecting and washing thallus, drying to obtain active bacteria powder, adding polyfructose according to viable count of Lactobacillus reuteri to make viable count not less than 1.0 x 108CFU/g, the addition of polyfructose is not less than 4g, gelatin is used for preparing a capsule wall material, PVP is used for making a bottom coat, beeswax is used for carrying out outer-layer coating, and a No. 0 capsule is packaged to obtain the Lactobacillus reuteri capsule.
18. Preparation of lactobacillus reuteri viable bacteria oral liquid
Inoculating Lactobacillus reuteri into liquid seed culture medium, and performing anaerobic culture at proper temperature to obtain probiotic seed liquid. Inoculating probiotic seed liquid into sterilized Lactobacillus reuteri fermentation culture medium according to total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 x 108CFU/ml。
19. Preparation of live bacillus putrescens capsule
Culturing fecal bacillus pusedi strain with liquid or solid culture medium, collecting and washing thallus, drying to obtain active powder, making capsule wall material with gelatin, using PVP as bottom coat, using beeswax to make outer layer coating, packaging with No. 0 capsule to obtain fecal bacillus pusedi capsule with viable count not less than 1.0 x 108CFU/g。
20. Preparation of polyfructose-containing live bacillus faecalis pratense capsule
Culturing the strain of the Bacillus putrescentiae in liquid or solid culture medium, collecting and washing the strain, drying to obtain active powder, and adding polyfructose according to the number of viable bacteria of the Bacillus putrescentiae to make the number of viable bacteria not less than 1.0 x 108CFU/g, polyfructose additive amount not less than 4g, making into capsule wall material with gelatin, using PVP as bottom coat, coating with Cera flava, and packaging with No. 0 capsule to obtain the Bacillus foeniculi Praeparata capsule.
21. Preparation of live bacillus putrescentiae oral liquid
Inoculating the Bacillus foeniculus pratenseAnd (3) performing aerobic anaerobic culture on the liquid seed culture medium at a proper temperature to obtain the probiotic seed liquid. Inoculating probiotic seed solution into sterilized fermentation culture medium of Bacillus putrescentiae according to total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 x 108CFU/ml。
22. Preparation of live rectum bacterium capsule
Culturing Eubacterium proctosphaeus strain with liquid or solid culture medium, collecting and washing thallus, drying to obtain active powder, making capsule wall material with gelatin, using PVP as bottom coat, coating with beeswax, and packaging with No. 0 capsule to obtain Eubacterium proctosphaeus capsule with viable count not less than 1.0 x 108CFU/g。
23. Preparation of live rectum bacterium capsule containing polyfructose
Culturing Eubacterium rectal strain with liquid or solid culture medium, collecting and washing the strain, drying to obtain active powder, and adding polyfructose according to the number of live bacteria of Eubacterium rectal strain to make the number of live bacteria not less than 1.0 × 108CFU/g, the addition of polyfructose is not less than 4g, gelatin is used for preparing a capsule wall material, PVP is used for making a bottom coat, beeswax is used for carrying out outer-layer coating, and the capsule is packaged by a No. 0 capsule, so that the eubacterium rectum capsule is obtained.
24. Preparation of live rectal bacillus oral liquid
Inoculating Eubacterium proctosphasum into liquid seed culture medium, and performing anaerobic culture at proper temperature to obtain probiotic seed liquid. Inoculating probiotic seed solution into sterilized Eubacterium rectal fermentation culture medium at total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 x 108CFU/ml。
25. Preparation of intestinal tract Roseburia bacterium viable bacteria capsule
Culturing Roseburia enterobacter with liquid or solid culture medium, collecting and washing thallus, and dryingDrying to obtain active bacteria powder, making into capsule wall material with gelatin, making PVP as bottom coat, coating with Cera flava, and packaging with No. 0 capsule to obtain Roseburia enteric-coated capsule with viable count not less than 1.0 x 108CFU/g。
26. Preparation of polyfructose-containing live bacteria capsule of Roseburia bailii in intestinal tract
Culturing Roseburia enterobacter with liquid or solid culture medium, collecting and washing thallus, drying to obtain active bacteria powder, adding polyfructose according to the number of active bacteria of Roseburia enterobacter, and making the number of active bacteria not less than 1.0 x 108CFU/g, polyfructose additive amount not less than 4g, making into capsule wall material with gelatin, using PVP as bottom coat, coating with Cera flava, and packaging with No. 0 capsule to obtain Roseburia enteric canal capsule.
27. Preparation of intestinal Rabysoria viable bacteria oral liquid
Inoculating Roseburia enterocolitica into liquid seed culture medium, and performing anaerobic culture at a proper temperature to obtain probiotic seed liquid. Inoculating probiotic seed liquid into sterilized intestinal Raosbai bacteria fermentation culture medium according to total inoculation amount of 1-3%, sealing with plastic film, standing for anaerobic culture, filtering, and aseptically packaging to obtain product with viable count not less than 1.0 x 108CFU/ml. Example 3 probiotic-modified functional test on human intestinal flora
Evaluation is carried out according to the evaluation method of the human trial experiment for regulating the functions of the intestinal flora in health food inspection and evaluation technical specification (2003) of Ministry of health.
1. Grouping of test feeding experiments
Table 1 grouping table for trial experiment
2. Human body test eating experimental method
Subjects were randomly divided into 27 groups of 10 individuals each, and feces from subjects were aseptically collected before subjects were fed for testing, and intestinal flora was examined by 16S rDNA sequencing as a reference for background levels.
According to the grouping conditions of Table 1, composition 1 is taken by group 1, composition 2 is taken by group 2, composition 3 is taken by group 3, composition 4 is taken by group 4, composition 5 is taken by group 5, composition 6 is taken by group 6, composition 7 is taken by group 7, composition 8 is taken by group 8, composition 9 is taken by group 9, composition 10 is taken by group 10, composition 11 is taken by group 11, composition 12 is taken by group 12, composition 13 is taken by group 13, composition 14 is taken by group 14, composition 15 is taken by group 15, composition 16 is taken by group 16, composition 17 is taken by group 17, composition 18 is taken by group 18, composition 19 is taken by group 19, composition 20 is taken by group 20, composition 21 is taken by group 21, composition 22 is taken by group 22, composition 23 is taken by group 23, composition 24 is taken by group 24, composition 25 is taken by group 25, composition 26 is taken by group 26, composition 27 is taken by group 27, and feces of, and (3) detecting the intestinal flora by 16S rDNA sequencing, comparing with the background level, and comparing the relative abundance of the intestinal flora with the increase fold.
3. Intestinal flora detection method
The fecal sample is firstly subjected to DNA extraction, PCR amplification is carried out on V3-V5 regions of 16S rDNA, and then 454 platform sequencing is carried out, wherein the sequencing direction is V5- > V3. The raw data for each sample averaged 7795 tags, reading around 400bp in length. The final tag number for analysis averaged 3235, reading around 265 bp.
The 16S analysis mainly adopts the Mothur software (http:// www.mothur.org/wiki/Mothur _ manual) including quality control, OTU clustering, annotation and other analysis, and analyzes the relative abundance of each species on the basis of completing the classification of the data species.
4. Results of the experiment
TABLE 2 comparison of abundance of sequencing data for various genera of human gut flora (fold increase compared to background levels before feeding)
Example 4 probiotic composition experiments on lowering blood glucose and lowering blood lipid
The evaluation is carried out according to the evaluation method of human body trial experiment for assisting the blood sugar and blood fat reduction function in health food inspection and evaluation technical Specification (2003) of the Ministry of health.
1. Preparation of the probiotic composition:
3 different compositions of probiotic single powder (capsules), bacterial powder and polyfructose (capsules), bacterial powder and culture solution (oral liquid) were prepared according to example 1.
2. Human body test feeding and test method:
270 patients with type II diabetes are selected according to the voluntary principle, wherein 200 men and 70 women have the age range of 43-75 years, and complications such as severe gravity center, liver and kidney and the like do not exist, and a design of comparing before, during and after eating trial is adopted.
The subjects were randomly divided into 27 groups of 10 subjects each, the subjects had unchanged type of the original therapeutic drugs, diet control and activity, and the groups of table 1 were assigned as groups, group 1 was administered composition 1, group 2 was administered composition 2, group 3 was administered composition 3, group 4 was administered composition 4, group 5 was administered composition 5, group 6 was administered composition 6, group 7 was administered composition 7, group 8 was administered composition 8, group 9 was administered composition 9, group 10 was administered composition 10, group 11 was administered composition 11, group 12 was administered composition 12, group 13 was administered composition 13, group 14 was administered composition 14, group 15 was administered composition 15, group 16 was administered composition 16, group 17 was administered composition 17, group 18 was administered composition 18, group 19 was administered composition 19, group 20 was administered composition 20, group 21 was administered composition 21, group 22 was administered composition 22, group 23 was administered composition 23, group 24 was administered composition 24, Group 25 was administered with composition 25, group 26 was administered with composition 26, and group 27 was administered with composition 27 1 time a day, and after meals for 30 consecutive days.
Monitoring the change of blood pressure, stool and urine, body weight of the patient, and determining fasting and 2 hours post-prandial blood glucose (using glucose oxidase method); blood lipids (total cholesterol TC, triglyceride TG and high density lipoprotein HDL-C) were measured.
3. And (4) judging the standard:
the effect is shown: the basic symptoms disappear, and the blood glucose after 2 hours of fasting or meal is reduced by no more than 30.0 percent compared with the blood glucose before treatment.
The method has the following advantages: the basic symptoms are obviously improved, and the blood sugar of 2 hours after the fasting and the meal is reduced by not more than 10.0 percent compared with the blood sugar before the treatment.
And (4) invalidation: the basic symptoms are not obviously improved, and the blood sugar of 2 hours after the fasting and the meal is reduced by less than 10.0 percent compared with the blood sugar before the treatment.
4. Human body test results:
after 30 days of test eating, compared with the patients before the test eating, the patients taking the probiotic compositions have no significant difference in blood pressure, excrement and urine and body weight, but fasting blood sugar and 2h postprandial blood sugar are obviously reduced, wherein the combined blood sugar reducing effect of the probiotics and the culture solution thereof is more significant, and the specific result is shown in table 3.
As for the patients taking the probiotic compositions of each group, compared with the patients before the test eating, the cholesterol and the triglyceride of the patients after the test eating for 30 days are obviously reduced, and the high-density lipoprotein is obviously increased, but the combined blood sugar reducing effect of the probiotics and the culture solution thereof is more obvious, and the specific result is shown in table 4.
Therefore, the probiotic and the culture solution combination thereof have obvious health care functions of assisting in reducing blood sugar and blood fat, and do not have damage to the health of tested people.
TABLE 3 blood sugar test results of trial population
Table 4 blood lipid test results of trial population
Note: (1) denotes P < 0.05; (2) denotes P <0.01
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made in the above embodiments by those of ordinary skill in the art without departing from the principle and spirit of the present invention.
Claims (9)
1. An edible composition comprising a culture of probiotic bacteria, wherein said culture of probiotic bacteria is obtained by culturing said probiotic bacteria in a culture medium.
2. The edible composition according to claim 1, wherein the probiotic is at least one selected from the group consisting of coprobacterium (Faecalibacterium), Eubacterium (Eubacterium), roseburium (Roseburia), Coprococcus (Coprococcus), Bifidobacterium (Bifidobacterium), vibrio butyrate (Butyrivibrio), lactobacillus (bactobacterium), and Lactococcus (Lactococcus).
3. The edible composition of claim 2, wherein the probiotic is selected from Eubacterium rectum (Eubacterium rectal), gluconobacter amylovora (Roseburia inuivorans), Roseburia enterobacter (Roseburia intestinalis), coprinus praecox (Faecalibacterium praussninzii), clostridium butyricum, bacillus coagulans, bifidobacterium bifidum, bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, lactobacillus delbrueckii subspecies bulgaricus, lactobacillus acidophilus, streptococcus thermophilus, lactobacillus casei subspecies casei, lactobacillus reuteri, lactobacillus bifidus, lactobacillus casei, lactobacillus crispatus, lactobacillus delbrueckii subspecies bulgaricus, lactobacillus fermentum, lactobacillus grignard, lactobacillus helveticus, lactobacillus johnsonii, lactobacillus plantarum, lactobacillus rhamnosus, lactobacillus lactis subspecies lactis, lactobacillus lactis subspecies, Lactococcus lactis of lactococcus cremoris, lactococcus lactis (diacetyl subspecies) and leuconostoc mesenteroides of enterococcus.
4. The edible composition of claim 1, wherein the medium comprises a carbon source, a nitrogen source, a growth factor, an inorganic salt, and water,
wherein,
the carbon source is at least one selected from the group consisting of saccharides, organic acids, alcohols, and lipids,
the nitrogen source is at least one selected from proteins and degradation products thereof with different degrees, ammonium salt and nitrate, and
the growth factor is at least one selected from the group consisting of vitamins, amino acids, purine and pyrimidine bases.
5. The edible composition according to any one of claims 1-4, wherein the edible composition is in the form of a capsule or an oral liquid.
6. A food product comprising an edible composition according to any one of claims 1 to 5.
7. Use of an edible composition according to any one of claims 1 to 5 in the preparation of a formulation for at least one of modulating gut flora, lowering blood glucose, lowering blood lipid and enhancing immunity.
8. Use of an edible composition according to any one of claims 1 to 5 or a food product according to claim 6 for modulating the intestinal flora of an animal.
9. A method of modulating gut flora comprising administering to an animal an edible composition according to any one of claims 1 to 5 or a food product according to claim 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310430441.0A CN104432001B (en) | 2013-09-18 | 2013-09-18 | Edible composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310430441.0A CN104432001B (en) | 2013-09-18 | 2013-09-18 | Edible composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104432001A true CN104432001A (en) | 2015-03-25 |
| CN104432001B CN104432001B (en) | 2018-01-12 |
Family
ID=52879348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310430441.0A Active CN104432001B (en) | 2013-09-18 | 2013-09-18 | Edible composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104432001B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770355A (en) * | 2016-03-17 | 2016-07-20 | 青岛根源生物技术集团有限公司 | Compound preparation for preventing necrotic enteritis of broilers and application of compound preparation |
| CN106562998A (en) * | 2015-10-12 | 2017-04-19 | 深圳华大基因研究院 | Applications of lactobacillus crispatus in treatment or prevention of uterus myoma related diseases |
| CN106666748A (en) * | 2017-01-02 | 2017-05-17 | 郑州国食科技有限公司 | Health food composition with effect of reducing cholesterol |
| WO2018027898A1 (en) * | 2016-08-12 | 2018-02-15 | 深圳华大基因研究院 | Faecalibacterium butyricigenerans and method for cultivation thereof and application thereof |
| WO2018045492A1 (en) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | Faecalibacterium longum and application thereof |
| CN109161494A (en) * | 2018-08-09 | 2019-01-08 | 北京市理化分析测试中心 | With the composite bacteria agent and its preparation method and application for adjusting immune function |
| CN109943510A (en) * | 2019-04-19 | 2019-06-28 | 华南农业大学 | One plant of lactic acid bacillus DU-106 and its application with probiotic properties |
| JP2019137631A (en) * | 2018-02-09 | 2019-08-22 | エースバイオプロダクト株式会社 | Hyperglycemia inhibitor |
| WO2022068273A1 (en) | 2020-09-29 | 2022-04-07 | 青岛蔚蓝生物股份有限公司 | Bacillus coagulans having blood glucose reduction efficacy, and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210454A (en) * | 2011-04-29 | 2011-10-12 | 张玉国 | Microbial compound preparation and preparation method thereof |
| CN102475725A (en) * | 2010-11-27 | 2012-05-30 | 赵宏伟 | Blood-sugar-reducing and eyesight-improving pill |
-
2013
- 2013-09-18 CN CN201310430441.0A patent/CN104432001B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475725A (en) * | 2010-11-27 | 2012-05-30 | 赵宏伟 | Blood-sugar-reducing and eyesight-improving pill |
| CN102210454A (en) * | 2011-04-29 | 2011-10-12 | 张玉国 | Microbial compound preparation and preparation method thereof |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106562998A (en) * | 2015-10-12 | 2017-04-19 | 深圳华大基因研究院 | Applications of lactobacillus crispatus in treatment or prevention of uterus myoma related diseases |
| CN105770355A (en) * | 2016-03-17 | 2016-07-20 | 青岛根源生物技术集团有限公司 | Compound preparation for preventing necrotic enteritis of broilers and application of compound preparation |
| CN109874329A (en) * | 2016-08-12 | 2019-06-11 | 深圳华大生命科学研究院 | A kind of production butyric acid is dwelt bacillus faecalis and its cultural method and application |
| WO2018027898A1 (en) * | 2016-08-12 | 2018-02-15 | 深圳华大基因研究院 | Faecalibacterium butyricigenerans and method for cultivation thereof and application thereof |
| US11191790B2 (en) | 2016-08-12 | 2021-12-07 | Bgi Shenzhen | Biologically pure Faecalibacterium butyricigenerans strain, composition including the same and method for treating ulcerative colitis |
| CN109874329B (en) * | 2016-08-12 | 2023-08-29 | 深圳华大生命科学研究院 | Fusarium butyricum and culture method and application thereof |
| WO2018045492A1 (en) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | Faecalibacterium longum and application thereof |
| US10799540B2 (en) | 2016-09-06 | 2020-10-13 | Bgi Shenzhen | Faecalibacterium longum and application thereof |
| CN106666748A (en) * | 2017-01-02 | 2017-05-17 | 郑州国食科技有限公司 | Health food composition with effect of reducing cholesterol |
| JP2019137631A (en) * | 2018-02-09 | 2019-08-22 | エースバイオプロダクト株式会社 | Hyperglycemia inhibitor |
| JP7235270B2 (en) | 2018-02-09 | 2023-03-08 | エースバイオプロダクト株式会社 | Blood sugar elevation inhibitor and method for producing same |
| CN109161494A (en) * | 2018-08-09 | 2019-01-08 | 北京市理化分析测试中心 | With the composite bacteria agent and its preparation method and application for adjusting immune function |
| CN109943510A (en) * | 2019-04-19 | 2019-06-28 | 华南农业大学 | One plant of lactic acid bacillus DU-106 and its application with probiotic properties |
| WO2022068273A1 (en) | 2020-09-29 | 2022-04-07 | 青岛蔚蓝生物股份有限公司 | Bacillus coagulans having blood glucose reduction efficacy, and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104432001B (en) | 2018-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104432001A (en) | Edible composition and use thereof | |
| TWI594758B (en) | Composition comprising bifidobacteria,processes for the preparation thereof and uses thereof | |
| CA2609617C (en) | Feline probiotic lactobacilli | |
| KR102303587B1 (en) | Use of probiotics in the treatment and/or prevention of psoriasis | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| JP6974483B2 (en) | New bifidobacteria probiotic strain | |
| CN109310715A (en) | For promoting the probiotics preparation of athletic performance | |
| CN112716982B (en) | Lactic acid bacteria-containing composition and use thereof | |
| JP2015535280A (en) | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract | |
| CN109451727A (en) | The composition and its preparation and application of probiotics and digestive ferment | |
| JP2009511469A (en) | Probiotics affecting fat metabolism and obesity | |
| JP2005538087A (en) | Probiotics for intestinal neuromuscular function | |
| CN102325464A (en) | Method for alleviating intestinal problems and novel bacterial strains therefor | |
| US20170106029A1 (en) | Composition and method for maintaining healthy kidney function | |
| JP6181153B2 (en) | Compositions containing probiotics and bee pollen / clay complexes, methods for their preparation, and use of the compositions in nutrition and therapeutics | |
| TW202200029A (en) | Composition for promoting defecation and use therefor | |
| JPWO2018003900A1 (en) | Composition for use in improving nutritional status | |
| CA3179561A1 (en) | Composition for improving gut microbiota | |
| CA2812909C (en) | Compositions and methods for augmenting kidney function | |
| Pop et al. | Pro and prebiotics foods that modulate human health | |
| JP2003252770A (en) | Agent for prevention, improvement and treatment of diabetic complication | |
| US11179426B2 (en) | Composition and method for maintaining healthy kidney function | |
| WO2019113023A9 (en) | Probiotics and methods of use | |
| Marini et al. | Pre-and probiotics for human skin | |
| JP7264952B2 (en) | COMPOSITION FOR IMPROVING ABDOMINAL BLOODING AND METHOD OF SCREENING SUBSTANCES OR COMPOSITIONS THAT HAVE ELIMINATION ACTIVITY FOR ABDOMINAL BLOODING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Edible composition and use thereof Effective date of registration: 20180917 Granted publication date: 20180112 Pledgee: China Minsheng Banking Corp Shenzhen branch Pledgor: BGI SHENZHEN Co.,Ltd. Registration number: 2018440020058 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200410 Granted publication date: 20180112 Pledgee: China Minsheng Banking Corp Shenzhen branch Pledgor: BGI SHENZHEN Co.,Ltd. Registration number: 2018440020058 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230601 Address after: No.7 Pengfei Road, Dapeng Office, Dapeng New Area, Shenzhen City, Guangdong Province, 518000 Patentee after: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Patentee before: BGI SHENZHEN Co.,Ltd. |